Cytori Therapeutics to Webcast Third Quarter Financial Results on November 9, 2009
More News related to CYTX
- Cytori Completes Enrollment in International Breast Cancer Reconstruction Study; Interim Data to Be Presented Dec. 12 at San Antonio Breast Cancer Symposium
- Cytori Reports 3rd Quarter 2009 Financial Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Cytori Therapeutics to Webcast Third Quarter Financial Results on November 9, 2009
- Cytori to Webcast Presentation at the 2009 BIOCOM Investor Conference on October 27
More News related to Press Releases
- Hoku Scientific (HOKU) Amends Poly Deal with Jinko Solar
- American International Group (AIG), Greenberg and Smith Settle Disputes
- Heska (HSKA) Announces Agreements with Roche for Blood Gas Product Supply/Affiliated Consumables
- AIG, Greenberg and Smith to settle all disputes
- DryShips (DRYS) Announces Exercise of Over-Allotment Option by Underwriters, Closes Convertible Senior Notes Offering for Net Proceeds of $448M
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics Inc. (NASDAQ: CYTX) will release and host a webcast to discuss its third quarter financial results on Monday, November 9, 2009 at 10:30 AM Eastern Time. The webcast will be available both live and by replay two hours after the call on the Company's website, under "Webcasts" on the Investor Relations page (http://ir.cytoritx.com).
Prior to the webcast at approximately 7:00 AM Eastern Time on November 9, Cytori will post a shareholder letter to its Investor Relations homepage, which will review Cytori's third quarter performance, provide an update on commercialization activities and discuss recent developments.
A telephone replay of the conference call webcast will be available through November 16, 2009 and can be accessed by dialing +1 800-406-7325 (Passcode: 4178319).
About Cytori
Cytori is committed to providing patients and physicians around the world with medical technologies, which harness the potential of adult stem and regenerative cells from adipose tissue. With the introduction of a family of medical devices, we have made a patient's own clinical grade stem and regenerative cells available to them at the point-of-care. The Celution(R) System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets, while we seek regulatory clearance for it in the United States. Our StemSource(R) product line is sold globally for cell banking and research applications.
Source: Cytori Therapeutics Inc.
Related Categories
Press ReleasesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
